Emtricitabine

( DrugBank: Emtricitabine / KEGG DRUG: Emtricitabine )


5 diseases
IDDisease name (Link within this page)Number of trials
265Lipodystrophy1
325Hereditary autoinflammatory syndrome1

13. Multiple sclerosis/Neuromyelitis optica


Clinical trials : 3,898 / Drugs : 2,785 - (DrugBank : 360) / Drug target genes : 265 - Drug target pathways : 239 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

25. Progressive multifocal leukoencephalopathy


Clinical trials : 31 / Drugs : 42 - (DrugBank : 23) / Drug target genes : 7 - Drug target pathways : 37 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

93. Primary biliary cholangitis


Clinical trials : 371 / Drugs : 286 - (DrugBank : 56) / Drug target genes : 35 - Drug target pathways : 105 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

265. Lipodystrophy


Clinical trials : 133 / Drugs : 176 - (DrugBank : 58) / Drug target genes : 30 - Drug target pathways : 102 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

325. Hereditary autoinflammatory syndrome


Clinical trials : 12 / Drugs : 18 - (DrugBank : 7) / Drug target genes : 2 - Drug target pathways : 37 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries